UpcomingPDUFA target action date

Amondys 45 (casimersen) and Vyondys 53 (golodirsen)

Sarepta Therapeutics (SRPT)

Marketer take

The confirmatory trial missed its primary endpoint and the company says FDA action could change labels, so DMD marketers should track this closely.

Sponsor company
Sarepta Therapeutics (SRPT)
Indication
Duchenne muscular dystrophy, sNDAs after confirmatory ESSENCE trial
Therapeutic area
Neurology, Rare disease
Event
PDUFA target action date
Date
Feb 28, 2027
Status
Upcoming
Source
SEC filing
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move